- Home
- ANIX vs ALVR Comparison
ANIX vs ALVR Comparison
Compare ANIX & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- ALVR
- Stock Information
- Founded
- ANIX 1982
- ALVR 2013
- Country
- ANIX United States
- ALVR United States
- Employees
- ANIX N/A
- ALVR N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANIX Health Care
- ALVR Health Care
- Exchange
- ANIX Nasdaq
- ALVR Nasdaq
- Market Cap
- ANIX 101.4M
- ALVR 87.7M
- IPO Year
- ANIX 1987
- ALVR 2020
- Fundamental
- Price
- ANIX $3.08
- ALVR $0.78
- Analyst Decision
- ANIX Strong Buy
- ALVR Sell
- Analyst Count
- ANIX 2
- ALVR 5
- Target Price
- ANIX $8.50
- ALVR $1.00
- AVG Volume (30 Days)
- ANIX 42.0K
- ALVR 134.3K
- Earning Date
- ANIX 10-29-2024
- ALVR 10-31-2024
- Dividend Yield
- ANIX N/A
- ALVR N/A
- EPS Growth
- ANIX N/A
- ALVR N/A
- EPS
- ANIX N/A
- ALVR N/A
- Revenue
- ANIX N/A
- ALVR N/A
- Revenue This Year
- ANIX N/A
- ALVR N/A
- Revenue Next Year
- ANIX N/A
- ALVR N/A
- P/E Ratio
- ANIX N/A
- ALVR N/A
- Revenue Growth
- ANIX N/A
- ALVR N/A
- 52 Week Low
- ANIX $2.15
- ALVR $0.58
- 52 Week High
- ANIX $5.13
- ALVR $2.49
- Technical
- Relative Strength Index (RSI)
- ANIX 41.08
- ALVR 46.47
- Support Level
- ANIX $2.95
- ALVR $0.75
- Resistance Level
- ANIX $3.11
- ALVR $0.79
- Average True Range (ATR)
- ANIX 0.12
- ALVR 0.05
- MACD
- ANIX -0.01
- ALVR -0.01
- Stochastic Oscillator
- ANIX 19.35
- ALVR 32.00
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.